Applying precision medicine to find a better solution

Alzheon’s valiltramiprosate/ALZ-801 is a late-stage oral anti-amyloid treatment having just completed Phase 3 testing for early symptomatic Alzheimer’s disease.

Development of valiltramiprosate, is based on ten years of Alzheon research into the biology of Alzheimer’s. Safety profile in valiltramiprosate studies remains favorable & consistent with prior data in over 3,000 AD patients, with no increased risk of vasogenic brain edema.

Using our pioneering precision medicine approach, we are initially focusing our development on the highest risk patients with two copies of the APOE4 gene (APOE4/4 homozygotes). Future trials aim to expand treatment to patients with only one copy of the APOE4 gene, and ultimately to prevention of onset of Alzheimer’s.